Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Selection criteria for lung-cancer screening.

Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, Chaturvedi AK, Silvestri GA, Riley TL, Commins J, Berg CD.

N Engl J Med. 2013 Feb 21;368(8):728-36. doi: 10.1056/NEJMoa1211776. Erratum in: N Engl J Med. 2013 Jul 25;369(4):394.

2.

Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.

Tammemägi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, Commins J, Berg CD.

PLoS Med. 2014 Dec 2;11(12):e1001764. doi: 10.1371/journal.pmed.1001764. eCollection 2014 Dec. Erratum in: PLoS Med. 2015 Jan;12(1):e1001787.

3.

Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R.

PLoS Med. 2017 Apr 4;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. eCollection 2017 Apr.

4.

Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.

Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK.

JAMA. 2016 Jun 7;315(21):2300-11. doi: 10.1001/jama.2016.6255.

5.

Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, Pinsky P, McMahon PM, de Koning HJ, Feuer EJ, Hazelton WD, Plevritis SK.

Cancer. 2014 Jun 1;120(11):1713-24. doi: 10.1002/cncr.28623. Epub 2014 Feb 27.

6.

Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.

Li K, Hüsing A, Sookthai D, Bergmann M, Boeing H, Becker N, Kaaks R.

Cancer Prev Res (Phila). 2015 Sep;8(9):777-85. doi: 10.1158/1940-6207.CAPR-14-0424. Epub 2015 Jun 15.

7.

Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.

Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, Margulis V.

Urol Oncol. 2016 Apr;34(4):167.e9-16. doi: 10.1016/j.urolonc.2015.10.011. Epub 2015 Nov 18.

PMID:
26602092
8.

Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.

Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, Riley TL, Commins J, Oken MM, Berg CD, Prorok PC.

J Natl Cancer Inst. 2011 Jul 6;103(13):1058-68. doi: 10.1093/jnci/djr173. Epub 2011 May 23.

9.

Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.

Krabbe LM, Svatek RS, Shariat SF, Messing E, Lotan Y.

Urol Oncol. 2015 Feb;33(2):65.e19-25. doi: 10.1016/j.urolonc.2014.06.009. Epub 2014 Jul 16.

PMID:
25044253
10.

Improving selection criteria for lung cancer screening. The potential role of emphysema.

Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, Alcaide AB, Pueyo J, Bastarrika G, Seijo LM, Pajares MJ, Pio R, Montuenga LM, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):924-31. doi: 10.1164/rccm.201410-1848OC.

PMID:
25668622
11.

A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor.

Wilson DO, Weissfeld J.

Lung Cancer. 2015 Jul;89(1):31-7. doi: 10.1016/j.lungcan.2015.03.021. Epub 2015 Mar 28.

12.

Application of risk prediction models to lung cancer screening: a review.

Tammemägi MC.

J Thorac Imaging. 2015 Mar;30(2):88-100. doi: 10.1097/RTI.0000000000000142. Review.

PMID:
25692785
13.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD; PLCO Project Team..

JAMA. 2011 Nov 2;306(17):1865-73. doi: 10.1001/jama.2011.1591. Epub 2011 Oct 26.

PMID:
22031728
14.

Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

Pinsky PF, Kramer BS.

J Natl Cancer Inst. 2015 Oct 19;107(11). pii: djv226. doi: 10.1093/jnci/djv226. Print 2015 Nov.

15.

The National Lung Screening Trial Premise of Null and Chest Radiography Equivalence Is Open to Question.

Reich JM, Kim JS.

AJR Am J Roentgenol. 2015 Aug;205(2):278-9. doi: 10.2214/AJR.14.13945.

PMID:
26204275
16.

Overdiagnosis in low-dose computed tomography screening for lung cancer.

Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, Chiles C, Black WC, Aberle DR; NLST Overdiagnosis Manuscript Writing Team..

JAMA Intern Med. 2014 Feb 1;174(2):269-74. doi: 10.1001/jamainternmed.2013.12738. Erratum in: JAMA Intern Med. 2014 May;174(5):828.

17.

Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.

Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, Kazerooni E.

Ann Intern Med. 2015 Apr 7;162(7):485-91. doi: 10.7326/M14-2086.

18.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD; PLCO Project Team..

J Natl Cancer Inst. 2010 May 19;102(10):722-31. doi: 10.1093/jnci/djq126. Epub 2010 May 4.

19.

Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.

O'Grady TJ, Kitahara CM, DiRienzo AG, Boscoe FP, Gates MA.

PLoS One. 2014 Sep 5;9(9):e106880. doi: 10.1371/journal.pone.0106880. eCollection 2014.

20.

Results of initial low-dose computed tomographic screening for lung cancer.

National Lung Screening Trial Research Team., Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S.

N Engl J Med. 2013 May 23;368(21):1980-91. doi: 10.1056/NEJMoa1209120.

Supplemental Content

Support Center